scholarly journals Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients

2021 ◽  
Author(s):  
Roman Reindl-Schwaighofer ◽  
Andreas Heinzel ◽  
Manuel Mayrdorfer ◽  
Rhea Jabbour ◽  
Thomas M. Hofbauer ◽  
...  
Keyword(s):  
Antibody Response ◽  
Kidney Transplant ◽  
Vaccine Dose ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals The Humoral Immune Response to BNT162b2 Vaccine Is Associated With Circulating CD19+ B Lymphocytes and the Naïve CD45RA to Memory CD45RO CD4+ T Helper Cells Ratio in Hemodialysis Patients and Kidney Transplant Recipients

2021 ◽  
Vol 12 ◽  
Author(s):  
Anila Duni ◽  
Georgios S. Markopoulos ◽  
Ioannis Mallioras ◽  
Haralampos Pappas ◽  
Efthymios Pappas ◽  
...  
Keyword(s):  
B Cells ◽  
Antibody Response ◽  
Kidney Transplant ◽  
B Lymphocytes ◽  
T Helper Cells ◽  
Vaccine Dose ◽  
Transplant Recipients ◽  
T Helper ◽  
Kidney Transplant Recipients ◽  
Helper Cells

BackgroundThe humoral and cellular immune responses to SARS-COV-2 vaccination remain to be elucidated in hemodialysis (HD) patients and kidney transplant recipients (KTRs), considering their baseline immunosuppressed status. The aim of our study was to assess the associations of vaccine-induced antibody responses with circulating lymphocytes sub-populations and their respective patterns of alterations in maintenance HD patients and KTRs.Materials and MethodsWe included 34 HD patients and 54 KTRs who received two doses of the mRNA-vaccine BNT162b2. Lymphocyte subpopulations were analyzed by flow cytometry before vaccination (T0), before the second vaccine dose (T1) and 2 weeks after the second dose (T2). The anti-SARS-CoV2 antibody response was assessed at T1 and at T2.Results31 HD patients (91.8%) and 16 KTRs (29.6%) became seropositive at T2. HD patients who became seropositive following the first dose displayed higher CD19+ B lymphocytes compared to their seronegative HD counterparts. A positive correlation was established between CD19+ B cells counts and antibody titers at all time-points in both groups (p < 0.001). KTRs showed higher naïve CD4+CD45RA+ T helper cells compared to HD patients at baseline and T2 whereas HD patients displayed higher memory CD45RO+ T cells compared to KTRs at T2. The naïve CD4+CD45RA to memory CD4+CD45RO+ T helper cells fraction was negatively associated with antibody production in both groups.ConclusionsOur study provides a potential conceptual framework for monitoring vaccination efficacy in HD patients and KTRs considering the correlation established between CD19+ B cells, generation of memory CD4+ T helper cells and anti SARS-CoV2 antibody response to vaccination.

scholarly journals Antibody response to a fourth mRNA Covid-19 vaccine boost in weak responder kidney transplant recipients

2021 ◽  
Author(s):  
Sophie Caillard ◽  
Olivier Thaunat ◽  
Ilies Benotmane ◽  
christophe masset ◽  
Gilles Blancho
Keyword(s):  
Antibody Response ◽  
Kidney Transplant ◽  
Organ Transplant ◽  
Vaccine Dose ◽  
Immunosuppressive Drugs ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Fourth Dose ◽  
Us Fda

The US FDA has recently authorized immunocompromised people to receive a third dose of mRNA Covid-19 vaccine following the two-doses regimen to further boost protection. Unfortunately, a non-negligible proportion of people treated with immunosuppressive drugs either do not respond or show only a weak response after a third boost and should, therefore, still be considered at risk of severe Covid-19. As of June 2021, we were granted the opportunity to offer a fourth vaccine dose to French solid organ transplant recipients who still showed a weak antibody response after the third dose. In this multicenter study, we demonstrate that that the protection conferred by a fourth dose is adequate for the majority of kidney transplant recipients

scholarly journals Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series

2022 ◽  
Author(s):  
Sophie Caillard ◽  
Olivier Thaunat ◽  
Ilies Benotmane ◽  
Christophe Masset ◽  
Gilles Blancho
Keyword(s):  
Antibody Response ◽  
Kidney Transplant ◽  
Messenger Rna ◽  
Case Series ◽  
Vaccine Dose ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

Safety and Antibody Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Kidney Transplant Recipients

2021 ◽  
Vol 05 (04) ◽  
Author(s):  
Ali AlShaqaq ◽  
Maher AlDemerdash ◽  
Abdulnaser AlAbadi ◽  
Baher Elgadaa ◽  
Najib Musaied ◽  
...  
Keyword(s):  
Antibody Response ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals Weak antibody response to 3 doses of mRNA vaccine in kidney transplant recipients treated with belatacept

2021 ◽  
Author(s):  
Nathalie Chavarot ◽  
Antoine Morel ◽  
Marianne Leruez‐Ville ◽  
Estelle Villain ◽  
Gillian Divard ◽  
...  
Keyword(s):  
Antibody Response ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals Diminished antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipients

2022 ◽  
Author(s):  
Ayman Al Jurdi ◽  
Rodrigo Benedetti Gassen ◽  
Thiago De Jesus Borges ◽  
Isadora Tadeval Lape ◽  
Leela Morena ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Vaccine Dose ◽  
Antibody Responses ◽  
Transplant Recipients ◽  
Wild Type ◽  
Kidney Transplant Recipients ◽  
Specific Antibodies ◽  
Antiviral Responses ◽  
The Third ◽  
Donor Specific Antibodies

Abstract: Background: Available SARS-CoV-2 vaccines have reduced efficacy against the Omicron variant in immunocompetent individuals. Kidney transplant recipients (KTRs) have diminished antiviral responses to wild-type SARS-CoV-2 after vaccination, and data on antiviral responses to SARS-CoV-2 variants, including the Omicron variant, are limited. Methods: We conducted a prospective, multi-center cohort study of 51 adult KTRs who received three doses of BNT162b2 or mRNA-1273. Blood and urine samples were collected before and four weeks after the third vaccine dose. The primary outcome was anti-viral antibody responses against wild-type and variants of SARS-CoV-2. Secondary objectives included occurrence of breakthrough SARS-CoV-2 infection and non-invasive monitoring for rejection using serum creatinine, proteinuria, donor-derived cell-free DNA and donor-specific antibodies. Sera from pre-pandemic healthy controls and KTRs were used for comparison. Results: 67% of KTRs developed anti-wild-type spike antibodies after the third vaccine dose, similar to the Alpha (51%) and Beta (53%) variants, but higher than the Gamma (39%) and Delta (25%) variants. No KTRs had neutralizing responses to the Omicron variant before the third vaccine dose. After the third dose, fewer KTRs had neutralizing responses to the Omicron variant (12%) compared to wild-type (61%) and Delta (59%) variants. Three patients (6%) developed breakthrough SARS-CoV-2 infection at a median of 89 days. No KTRs developed allograft injury, de novo donor-specific antibodies or allograft rejection. Conclusion: In KTRs, a third dose of mRNA vaccines increases antibody responses against wild-type and variants of SARS-CoV-2, while neutralizing responses to the Omicron variant remain markedly reduced.

scholarly journals Antibody Response to mRNA Vaccines against SARS-CoV-2 with Chronic Kidney Disease, Hemodialysis, and after Kidney Transplantation

2021 ◽  
Vol 11 (1) ◽  
pp. 148
Author(s):  
Lukas Buchwinkler ◽  
Claire Anne Solagna ◽  
Janosch Messner ◽  
Markus Pirklbauer ◽  
Michael Rudnicki ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Transplantation ◽  
Kidney Disease ◽  
Antibody Response ◽  
Kidney Transplant ◽  
Mycophenolic Acid ◽  
Calcineurin Inhibitors ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Factors Associated

Most trials on mRNA vaccines against SARS-CoV-2 did not include patients with chronic kidney disease (CKD), hemodialysis (HD) patients, or kidney transplant recipients (KTR). However, those patients have a higher risk for a severe course of COVID-19 disease and mortality. Available literature has demonstrated a reduced efficacy of mRNA vaccines in HD patients and KTR, while data on CKD patients is scarce. Additionally, factors associated with non-response are poorly understood and not well characterized. We assessed antibody (AB) response (n = 582, 160 CKD patients, 206 patients on HD, 216 KTR) after the administration of two doses of a mRNA-vaccine with either BNT162b2 or mRNA-1273. AB measurements were carried out after a median of 91 days after first vaccinations, demonstrating non-response in 12.5% of CKD patients, 12.1% of HD patients, and 50% of KTR. AB titers were significantly higher in CKD patients than in HD patients or KTR. Factors associated with non-response were treated with rituximab in CKD patients, the use of calcineurin inhibitors in HD patients and older age, and the use of BNT162b2, mycophenolic acid, or glucocorticoids and lower hemoglobin levels in KTR. This study contributes to the understanding of the extent and conditions that predispose for non-response in patients with impaired kidney function.

scholarly journals Risk Factors Associated With an Impaired Antibody Response in Kidney Transplant Recipients Following 2 Doses of the SARS-CoV-2 mRNA Vaccine

2021 ◽  
Vol 8 (1) ◽  
pp. e1257
Author(s):  
Stephanie G. Yi ◽  
Linda W. Moore ◽  
Todd Eagar ◽  
Edward A. Graviss ◽  
Duc T. Nguyen ◽  
...  
Keyword(s):  
Risk Factors ◽  
Antibody Response ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Factors Associated
Sign in / Sign up

Export Citation Format

Share Document